ClinicalTrials.gg
CompletedNCT05304364Updated Feb 13, 2025

Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)

A Phase 1 interventional study of Combination Product: Naltrexone in Opiod Use Disorder, sponsored by Delpor, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Delpor, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing naltrexone in Behavior, Addictive — 1 open to participants now, 1 under way, none of them phase 3. Naltrexone · Behavior, Addictive.

Enrollment
14th of 14
10 · median 68
Started
2022
the only one that year
Phase 1
2 of 14
none open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Delpor, Inc.

Among the 14 studies testing naltrexone in Behavior, Addictive, this one is the 14th largest by enrollment, is the only one that started in 2022, is one of 2 in phase 1, and was the 13th registered.

Behavior, Addictive

521 studies on the registry are indexed under Behavior, Addictive; 124 are open to participants now.

Browse Behavior, Addictive studies →

Open to participants now

1 of the 14 studies testing naltrexone in Behavior, Addictive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Behavior, Addictive studies recruiting now, 44 (55%) set no upper age limit and 34 (43%) stop at 75 or younger; 7 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing naltrexone in Behavior, Addictive, or all of them as a file.
02

Study summary

This is an Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Naltrexone HCL to DLP-160 (Naltrexone implant) to Intramuscular Vivitrol®

Read the detailed description

This study is first-in-man clinical study of DLP-160, a Naltrexone implant product. The study is an open-label, single sequence design aimed at assessing the safety and tolerability of DLP-160 and evaluating its utility in achieving a PK profile that is comparable to the marketed oral and injectable forms of Naltrexone.

Initially, a group of 2 healthy volunteers will receive the Naltrexone HCL followed by DLP-160 implant as a sentinel group. The safety and tolerability of the DLP-160 implant will be assessed in the sentinel group for at least 28 days prior to any other volunteers being implanted with DLP-160 in the study. Only if the safety and tolerability data, obtained from the sentinel group, are considered acceptable by the Investigator, will the remainder of healthy volunteers commence treatment in the study.

Healthy volunteers will be enrolled and implanted with DLP-160 involving treatment of each study participant consisting of 3 sequential treatment periods with a washout period between treatments.

  1. Naltrexone HCL treatment (oral; 50 mg/day) (Day -6 to Day -2);
  2. Washout (Day -1);
  3. DLP-160 implant treatment (up to 123 days);
  4. DLP-160 removal and washout (1 day);
  5. Vivitrol® treatment (single intramuscular injection with a 30 day follow up);
  6. Follow up to completion of study participation (7 days).
03

Conditions studied

  • Opiod Use Disorder

Keywords

  • Naltrexone
  • Addiction
  • Mental Health
  • Implant
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
  2. Adult males and females, 18 to 50 years of age (inclusive) at the time of screening.
  3. (BMI) greater than or equal to 18.0 and lesser than or equal to 30.0 kg/m2, with a body weight (to 1 decimal place) greater than or equal to 50 kg.
  4. Medically healthy without abnormalities (in the opinion of the Investigator) at the screening visit and prior to administration of the first study dose on study Day -6, including:

    1. Physical examination without any clinically significant findings.
    2. Systolic blood pressure in the range of 90 to 160 mmHg (inclusive) and diastolic blood pressure in the range of 50 to 95 mmHg (inclusive) after 5 minutes in supine (or semi-supine) position.
    3. Heart rate (HR) in the range of 45 to 100 bpm (inclusive) after 5 minutes rest in a supine (or semi-supine) position.
    4. Body temperature (tympanic or oral) in the range 35.5°C to 37.7°C (inclusive).
    5. No clinically significant findings in serum chemistry, haematology, coagulation, and urinalysis tests.
    6. Triplicate 12-lead (taken after the volunteer has been supine (or semi-supine) for at least 5 minutes) with a corrected using the Fridericia method (QTcF) lesser than or equal to 450 msec for males and lesser than or equal to 470 msec for females and no clinically significant abnormalities.

    Note: Minor abnormalities or deviations outside the normal ranges for any of the clinical testing (laboratory tests, ECG, vital signs) may be repeated at the discretion of the Investigator. Such abnormalities or deviations are acceptable for participation in the study if judged to be not clinically significant by the Investigator. count and coagulation measures must be within normal limits.

  5. Female volunteers must:

    1. Be of nonchildbearing potential i.e., be surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before screening) or be , where menopause is defined as 12 months of amenorrhea in the absence of other biological causes (females under the age of 55 years must have a documented serum follicle stimulating hormone (FSH) level greater than 40mIU/mL to confirm menopause).
    2. If of (defined as any female who has experienced menarche and who has not undergone surgical sterilisation and is not postmenopausal), the participant:

      • Must have a negative serum test at the screening visit and a negative urine pregnancy test within 24 hours prior to the start of study drug.
      • Must not be breastfeeding, lactating or planning pregnancy during the study period.
      • Must agree not to attempt to become pregnant.
      • If not exclusively in same-sex relationships, must agree to use adequate (which is defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner); after signing consent, during the study, and at least 35 days after the last dose of study drug;
      • Must agree to not donate ova for at least 35 days after the last dose of study drug.
  6. Male participants, if not surgically sterilised, must agree to:

    1. Not donate sperm after signing consent, during the study, and at least 95 days after the last dose of study drug.
    2. If engaging in sexual intercourse with a female partner who could become pregnant, use a condom in addition to having the female partner use a highly effective contraceptive method.
    3. Have suitable venous access for blood sampling.
  7. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be (participants with resolved childhood asthma may be included in the study).
  2. Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.
  3. Liver function test results elevated more than 1.5-fold above the (ULN) for gamma glutamyl transferase (GGT), (total, conjugated and unconjugated), alkaline phosphatase (ALP), (AST) or alanine aminotransferase (ALT). Volunteers with ALP and/or ALT/AST above the limits specified may be included, at the discretion of the Investigator, if the levels are unaccompanied by clinical signs and are determined to be normal variants.
  4. Positive test results for active (HIV-1 or HIV-2), surface antigen (HBsAg) or virus (HCV) antibodies at the screening visit.
  5. Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs (prior gall bladder and/or appendix removal is not exclusionary if deemed appropriate by the Investigator).
  6. Estimated (CrCl) less than 80 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.
  7. Presence of clinically significant skin disorders (such as, but not limited to, skin cancer, psoriasis, eczema, or atopic dermatitis), evidence of recent sunburn, scar tissue, tattoo, open sore, body piercing or branding at the intended placement site that would interfere with the placement procedure or interfere with implant site assessments as determined by the Investigator.
  8. History of abnormal scar formation or family history of keloid formation.
  9. Known to titanium, implant materials or the procedure of implant placement.
  10. Previously defined hypersensitivity to Naltrexone.
  11. Known hypersensitivity or allergy to lidocaine or any local anaesthetic agent of the amide type (local anaesthetic used during placement and removal procedures).
  12. History of substance abuse, in the opinion of the Investigator.
  13. History of alcohol abuse (defined as more than an average of 14 standard drinks per week or regular consumption of more than 4 standard drinks on any one day; where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc./Vol], 100 mL wine [12% Alc./Vol], 30 mL spirit [40% Alc./Vol]).
  14. Positive drugs of abuse or alcohol breath test results at the screening visit or prior to the first study drug administration on Day -6 and at check-in on Day -2.
  15. Use of any prescription or over-the-counter medication (including herbal products, and hormone supplements) within 10 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration - exceptions include for females, occasional use of paracetamol (doses of 500 mg up to every 6 hours or 2 g per day maximum for no more than 3 consecutive days), ibuprofen (doses of 400 mg up to every 6 hours or 1.2 g per day maximum for no more than 3 consecutive days), topical ointments, and vitamins or dietary supplements.
  16. Demonstrated clinically significant (required intervention, e.g., emergency room visit, epinephrine administration) allergic reactions (e.g., food, drug, or atopic reactions, asthmatic episodes) which, in the opinion of the Investigator, would interfere with the volunteer's ability to participate in the trial.
  17. For women of , a positive serum pregnancy test at the screening visit or a positive urine pregnancy test (with confirmatory serum pregnancy test) prior to the first study drug administration on Day -6 and at check-in on Day -2.
  18. Females who are breastfeeding or planning to breast feed at any time during the study.
  19. Donation of blood or plasma within 30 days prior to first study drug administration, or loss of whole blood of more than 500 mL within 30 days prior to first study drug administration, or receipt of a blood transfusion within 1 year of first study drug administration.
  20. Intolerance of direct venepuncture.
  21. Treatment with an drug (or device) in another clinical trial within 30 days or 5 half-lives of the other investigational drug (whichever is longer) prior to the first administration of study drug in this trial.
  22. Anticipated surgical procedure or current painful condition that is likely to require opioid analgesia during the trial.
  23. Any other condition or prior therapy that in the opinion of the Investigator would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    DLP-160 alpha-10

    One time single Naltrexone Implant for a duration of 123 days

    Combination Product: Combination Product: Naltrexone

Interventions

  • Combination productCombination Product: Naltrexone

    Drug page: Naltrexone

    Naltrexone Implant

    Also known as: DLP-160

06

What researchers measure

Primary outcomes

  1. DLP-160 Adverse Events

    Determine the number and percent of patients experiencing a treatment-emergent adverse event

    Time frame: Day 1 to Day 120

  2. DLP-160 Local Tolerance

    Evaluate the incidence of local site reactions

    Time frame: Day 1 to Day 120

  3. Tolerability of DLP-160 Implantation and Removal Procedures

    Assess the incidence of local site reactions and/or Adverse Events (AEs) reported during the implantation and removal procedure

    Time frame: Day 1 to Day 120

Secondary outcomes

  1. Oral Pharmacokinetic (PK) Profile

    Measure the plasma concentration of Naltrexone, 6-β-naltrexol and active moiety (Naltrexone + 6-β-naltrexol) following: • Repeated oral administrations Naltrexone HCL

    Time frame: 24 hours

  2. Implant Pharmacokinetic (PK) Profile

    Measure the plasma concentration of Naltrexone, 6-β-naltrexol and active moiety (Naltrexone + 6-β-naltrexol) following: • Following treatment switch from oral Naltrexone HCL to subcutaneous placement of one DLP-160 implant

    Time frame: 4 months

  3. IM Naltrexone PK Profile

    Measure the plasma concentration of Naltrexone, 6-β-naltrexol and active moiety (Naltrexone + 6-β-naltrexol) following: • Following treatment switch from one DLP-160 implant to a single IM dose of Vivitrol®.

    Time frame: 1 month

  4. Evaluate the Drug Output of the DLP-160 Implant

    Evaluate the amount of Naltrexone drug substance remaining in the DLP-160 implant drug reservoir following its removal and estimating daily drug output of the DLP-160 implant.

    Time frame: 4 months

07

Study locations

1 site
  • CMAX
    Adelaide, South Australia 5000, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Oct 2022, 6 months.

Of 24 phase 1 interventional studies under Behavior, Addictive, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 31, 2022
StartActual
Mar 22, 2022
Primary completionActual
Oct 21, 2022
CompletionActual
Nov 19, 2022
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05304364
Lead sponsor
Delpor, Inc.
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Mar 22, 2022
Primary completion
Oct 21, 2022
Completion
Nov 19, 2022
Last update
Feb 13, 2025

Study contacts

Alex Choo, MD
principal investigator · CMAX

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion